Nov 26, 2013 at 11:55 | Source: Reuters
If the offer is fully subscribed, the number of Taro shares to be purchased in the offer represents approximately 4.6 to 5.3 percent of the unit's total outstanding shares.
Nov 18, 2013 at 12:38 | Source: CNBC-TV18
Bino Pathiparampil, vice president research, Institutional Equities picks Sun Pharma as his top pick in the sector, but is cautious on Lupin as he sees some headwinds for the stock over the next two years.
Nov 13, 2013 at 13:25 | Source: Moneycontrol.com
Taro's sales grew 28 percent year-on-year. Its operating profits grew faster at 46 percent led by 740 basis points margin expansion. Religare has hiked its target price to Rs 725.
Nov 13, 2013 at 11:00 | Source: Moneycontrol.com
Sun Pharma is up over 3 percent after Taro's September quarter earnings beat expectations. Taro's sales grew 28 percent year-on-year. Its operating profits grew faster at 46 percent led by 740 basis points margin expansion. Religare has hiked its target price to Rs 725 solely.
Nov 13, 2013 at 10:19 | Source: Moneycontrol.com
Sun Pharma is the biggest gainer among largecaps in the Sensex, rising 3.5 percent ahead of second quarter earnings. Taro numbers too helped the stock rally. Net income rose 47.2 percent Y-o-Y to USD 96.3 million and net sales jumped 27.5 percent to USD 205.3 million in the quarter gone by.
Nov 12, 2013 at 18:56 | Source: CNBC-TV18
Analysts expect profit after tax to grow 48 percent year-on-year to Rs 1,340 crore in the quarter gone by. Its reported PAT for Q2FY13 was Rs 319.6 crore, but there was an exceptional outflow of Rs 583.5 crore on Protonix generic; hence reported PAT stood at Rs 903 crore for that quarter.
Oct 08, 2013 at 13:42 | Source: CNBC
The IMF's warning follows comments from Japanese finance minister Taro Aso on Friday, who sounded fears over how the political impasse in the US could lead to further US dollar selling and yen buying, which would be bad news for Japanese exporters and the success of Abenomics overall.
Sep 23, 2013 at 15:13 | Source: Moneycontrol.com
Glenmark Generics Inc., USA the subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Admiistration (USFDA) for Desoximetasone Ointment USP, 0.25 percent their generic version of Topicort by Taro Pharmaceuticals USA Inc and shipping will commence immediately.
Aug 30, 2013 at 13:05 | Source: CNBC-TV18
The stock movement is on the back of news that its subsidiary Taro Pharmaceutical has entered an exclusive licensing and co-development agreement with Novabiotics for its investigational new drug.
Aug 22, 2013 at 11:23 | Source: Moneycontrol.com
Morgan Stanley believes, Sun Pharma's business growth drivers are intact with high-quality domestic formulations, non-Taro US business and the new drivers like Sun Pharma Advancing Research Company (SPARC) and balance sheet shaping up well.